Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

667
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
667
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

779
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
779
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.1K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.1K
Drug Therapy01:28

Drug Therapy

411
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
411
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose-Dependent Escitalopram-Induced Anejaculation and Anorgasmia: Rapid Reversal After Discontinuation and Bupropion Therapy.

American journal of therapeutics·2026
Same author

Stoichiometric dependence of the structural and electronic properties of HfX<sub>2(1-<i>x</i>)</sub>X<sub>2<i>x</i></sub> (X = S, Se, Te) monolayers.

Physical chemistry chemical physics : PCCP·2026
Same author

Authors' Response, "Reply to the comments on Reporting guidelines for Case Reports In Mental health and Psychiatry (CRIMP)".

Indian journal of psychiatry·2026
Same author

Accelerated left dorsolateral prefrontal cortex transcranial magnetic stimulation for suicidality in patients with depressive disorders: A case series.

Indian journal of psychiatry·2025
Same author

Study protocol for identifying resting brain functional connectivity markers of response to continuous Theta Burst Stimulation and cathodal transcranial Direct Current Stimulation in patients with schizophrenia with persistent auditory hallucinations.

Wellcome open research·2025
Same author

Determinants of illicit substance use among young adults in a coastal town of South India: A mixed-methods study.

Indian journal of psychiatry·2025

Related Experiment Video

Updated: Apr 5, 2026

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
07:38

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats

Published on: May 27, 2021

9.0K

Amisulpride Augmentation in Acute Catatonia.

Manu Arora1, Rakesh Banal, Samir K Praharaj

  • 11Department of Psychiatry, Government Medical College, Jammu, India; 2Department of Psychiatry, Kasturba Medical College, Manipal, India; and 3Department of Pharmacology, Government Medical College, Jammu, India.

American Journal of Therapeutics
|August 14, 2015
PubMed
Summary

Adding low-dose amisulpride to lorazepam effectively treated catatonia in all patients within three days. This combination therapy offers a reliable strategy for managing catatonic symptoms when benzodiazepines alone are insufficient.

More Related Videos

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

811
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
07:38

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats

Published on: May 27, 2021

9.0K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

811
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.9K

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Benzodiazepines are the primary treatment for catatonia.
  • A significant portion of patients do not respond adequately to benzodiazepines alone.

Purpose of the Study:

  • To evaluate the efficacy of augmenting lorazepam with low-dose amisulpride for catatonia.
  • To assess the resolution rate and speed of catatonic symptoms using this combined treatment.

Main Methods:

  • A study involving fifteen patients diagnosed with catatonia.
  • Treatment consisted of oral lorazepam (2-4 mg) combined with oral amisulpride (100 mg).
  • Catatonic symptoms were assessed daily using the Bush Francis Catatonia Rating Scale (BFCRS).

Main Results:

  • Complete resolution of catatonic symptoms was observed in all patients by the third day of treatment.
  • A statistically significant reduction in the total BFCRS score was noted over time (F = 181.38, P < 0.001).
  • A large effect size (partial η = 0.96) indicated a robust treatment effect.

Conclusions:

  • Augmenting lorazepam with low-dose amisulpride is a dependable and effective strategy for managing catatonia.
  • This combination therapy shows promise for patients unresponsive to standard benzodiazepine treatment.